$0.7308
-0.0592-7.49%
Last update: Nov 5, 6:32 PM
Metagenomi Therapeutics Inc (MGX) Stock Price, Quote, News & History
MGXNASDAQ
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.
You can purchase shares of Metagenomi Therapeutics (NASDAQ:MGX) through any online brokerage.
Other companies in Metagenomi Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Metagenomi Therapeutics has a consensus price target of $10.38.
The stock price for Metagenomi Therapeutics (NASDAQ: MGX) is $0.7174 last updated November 5, 2026 at 6:32 PM EST.
There are no upcoming dividends for Metagenomi Therapeutics.
Metagenomi Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Metagenomi Therapeutics.
Metagenomi Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature...
